HeartSciences Inc. (HSCS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 47.7 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While HSCS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.61) and Max Pain ($3.79) forces dealer call-delta covering toward $5.51.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
HeartSciences Inc. (HSCS) surged +7.12% to $3.61, trading at 55% of its 52-week range ($1.63 – $5.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Fortitude Mining Holdings, Inc. ("Fortitude" or the "Company"), a vertically integrated digital asset mining platform anchored in Zcash, today announced that its 15-megawatt (MW) facility in Aurora,
Here is how HeartSciences Inc. (HSCS) and ImmunityBio (IBRX) have performed compared to their sector so far this year.
Shareholder Special Meeting Scheduled for November 19, 2026Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transactionHeartSciences Board of Directors unani
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HSCS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HSCS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, HeartSciences Inc. (HSCS) ranks #560 by composite RQD confidence (43/100, grade D-) and #843 by equity capitalization ($17.5M). Within this direct 5-issuer industry benchmark cohort, MLSS leads on earnings valuation at 5.0x trailing P/E, while HSCS leads on capital efficiency and profitability with -35.0% ROIC and 59.1% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with HSCS at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HSCS
ACTIVE
HeartSciences Inc. | D- | 43/100 | — | 59.1% | -35.0% | +7.12% | $17.5M | Benchmark Subject |
| LFWD Lifeward Ltd. | D | 46/100 | — | 96.0% | -35.0% | +2.78% | $16.7M | /lfwd-vs-hscs → |
| CUPR Cuprina Holdings (Cayman) Limited (Class A) | E | 32/100 | — | -1.3% | -35.0% | -1.07% | $14.1M | /cupr-vs-hscs → |
| CLGN CollPlant Biotechnologies Ltd | D | 50/100 | — | 64.8% | -35.0% | +11.39% | $12.7M | /clgn-vs-hscs → |
| MLSS Milestone Scientific Inc. | D- | 43/100 | 5.0x | 71.4% | -35.0% | -0.54% | $28.6M | /mlss-vs-hscs → |
In its most recent audited fiscal period (FY2025, filed 2026-04-30), HeartSciences Inc. (HSCS) reported GAAP revenue of $4.3K (-0.7% vs. FY2024 revenue of $4.3K , and -76.8% cumulative change since FY2023) , GAAP net income of -$9.1M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (-0.2% YoY). On the balance sheet, HSCS closed FY2025 with $4.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $4.3K | -$9.1M | -$7.4M | -$7.4M | $4.2M | — |
| FY2024 (FY) | 2025-04-30 | $4.3K | -$8.8M | -$7.4M | -$7.4M | $5.7M | — |
| FY2023 (FY) | 2024-04-30 | $18.6K | -$6.6M | -$6.1M | -$6.1M | — | — |
As of 2026-11-01, HeartSciences Inc. (NASDAQ: HSCS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.61 (+7.12% 1D, market cap $17.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HSCS ranks #560 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), HSCS carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 59.1%, and ROIC of -35.0%. By comparison, LFWD (Lifeward Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and CUPR (Cuprina Holdings (Cayman) Limited (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M). Among the 5-stock peer group, MLSS leads on earnings multiple (5.0x) while HSCS leads on capital efficiency (-35.0% ROIC).
Per HSCS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001468492), HeartSciences Inc. generated $4.3K in revenue (-0.7% YoY), -$9.1M in net income, and -$7.4M in free cash flow against $4.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
HSCS last traded at $3.61 (+7.12% on volume of 75,959 shares), positioning the stock 0.00% above its 50-day simple moving average ($3.61) and +32.72% above its 200-day simple moving average ($2.72). Across its 52-week range of $1.63 to $5.25, HSCS sits at the 54.7% percentile with a 14-day RSI of 47.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.16 to $4.06).
Why HSCS Stock surged +7.12% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.